uniQure (QURE) Insider Madhavan Balachandran Sells 11,685 Shares

Insider Buying and Selling at uniQure N.V.

Recent regulatory filings show that Madhavan Balachandran transacted 11,685 shares of uniQure N.V. (NasdaqGS: QURE) on June 17, 2026. This move comes during a period filled with executive stock activity at the clinical-stage biotechnology company, providing market watchers with fresh data points on insider sentiment.

Recent Insider Moves at the Firm

Executive trading at the biotechnology firm has been active over the summer months. Chief Medical Officer Walid Abi-Saab sold 1,434 shares on June 26, 2026, at an average price of $46.86, resulting in a total value of $67,197.24. CEO Matthew Kapusta has also been active, including a purchase of 4,128 shares on June 24, 2026, at $31.71 per share, alongside a planned sale of 4,128 shares on the same day. Kapusta also completed a larger transaction earlier on June 17, 2026, buying 62,581 shares at $19.39 each while also completing a planned sale of 164,429 shares at an average price of $44.32.

Stock Performance and Market Context

Shares of uniQure trade at $45.77, holding well above their 52-week low of $8.73 while staying below the 52-week high of $71.50. The stock changes hands above its 50-day moving average of $40.20 and comfortably past its 200-day moving average of $29.66. Because the firm operates as a development-stage therapeutics provider with an active clinical pipeline, price swings remain common.

Wall Street Ratings and Price Targets

Analyst sentiment spans several viewpoints as firms update their outlooks. Barclays adjusted its stance on October 5, 2026, moving to an equal-weight rating with a $28.00 price target. RBC Capital maintained an outperform rating on October 2, 2026, while lowering its target to $48.00 from $65.00. Goldman Sachs kept a neutral rating with a $31.00 target on September 30, 2026. Earlier in the summer, Wells Fargo maintained an overweight rating on July 30, 2026, with a $75.00 target, while Wolfe Research upgraded the stock to outperform on the same day with a $65.00 target. HC Wainwright & Co. kept a buy rating with an $80.00 target on June 29, 2026, and Mizuho maintained an outperform rating on June 25, 2026, setting a $68.00 target. Across the broader community, analysts hold a consensus strong buy rating with a mean price target of $61.46.

About uniQure N.V.

Based in Amsterdam, the Netherlands, uniQure N.V. focuses on developing gene therapies for patients with rare and challenging medical conditions. Its portfolio features treatments such as HEMGENIX for hemophilia B alongside clinical candidates targeting Huntington's disease, epilepsy, ALS, and Fabry disease.

What's Ahead for uniQure N.V.

Investors will look toward the company's next earnings report scheduled for November 9, 2026, for further updates on clinical trials and financial progress. Insider transactions remain subject to standard reporting rules under SEC guidelines and offer insight into how leadership manages personal holdings.